Gilead Sciences Inc (GILD) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Total Assets Chart for Gilead Sciences Inc
Gilead Sciences Inc (GILD) total assets for FY2025 were USD 59.0B, a 0.0% change from FY2024. Gilead Sciences Inc's total assets grew from USD 12.5M in 1990 to USD 59.0B in 2025 (472084.0% over 35 years). Total assets compound annual growth rate: 5-year CAGR of -2.9%, 10-year CAGR of 1.3%, 20-year CAGR of 14.8%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $162.47B
- Implied Share Price
- $130.86
- Enterprise Value
- $182.45B
- Revenue (TTM)
- $30.46B
- EBITDA
- $15.24B
- Profit Margin
- -10.64%
- Trailing P/E
- —
- Forward P/E
- 15.22
- Price/Book (MRQ)
- 14.30
- Price/Sales (TTM)
- 5.33
- EV/EBITDA
- 12.25
- EV/Revenue
- 5.99
- Dividend Yield
- 2.44%
- Book Value
- $9.46
- Free Cash Flow (FY2025)
- $9.46B
- Free Cash Flow Yield
- 5.82%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.